

## Contents

List of Contributors	<i>XVII</i>
Preface	<i>XXI</i>
A Personal Foreword	<i>XXIII</i>

### Part One Introduction 1

<b>1</b>	<b>Metabolism in Drug Development</b>	<b>3</b>
	<i>Bernard Testa</i>	
1.1	What? An Introduction	3
1.2	Why? Metabolism in Drug Development	4
1.2.1	The Pharmacological Context	4
1.2.2	Consequences of Drug Metabolism on Activity	6
1.2.3	Adverse Consequences of Drug Metabolism	7
1.2.4	Impact of Metabolism on Absorption, Distribution, and Excretion	10
1.3	How? From Experimental Results to Databases to Expert Software Packages	11
1.3.1	The Many Factors Influencing Drug Metabolism	11
1.3.2	Acquiring and Interpreting Experimental Results	13
1.3.3	Expert Software Tools and Their Domains of Applicability	14
1.3.4	Roads to Progress	16
1.4	Who? Human Intelligence as a Conclusion	17
	References	19

### Part Two Software, Web Servers and Data Resources to Study Metabolism 27

<b>2</b>	<b>Software for Metabolism Prediction</b>	<b>29</b>
	<i>Lu Tan and Johannes Kirchmair</i>	
2.1	Introduction	29
2.2	Ligand-Based and Structure-Based Methods for Predicting Metabolism	30
2.3	Software for Predicting Sites of Metabolism	38

2.3.1	Knowledge-Based Systems	38
2.3.2	Molecular Interaction Fields	39
2.3.3	Docking	39
2.3.4	Reactivity Models	40
2.3.5	Data Mining and Machine Learning Approaches	41
2.3.6	Shape-Focused Approaches	42
2.4	Software for Predicting Metabolites	43
2.4.1	Knowledge-Based Systems	44
2.4.2	Data Mining and Machine Learning Approaches	46
2.4.3	Molecular Interaction Fields	46
2.5	Software for Predicting Interactions of Small Molecules with Metabolizing Enzymes	46
2.6	Conclusions	48
	References	49
<b>3</b>	<b>Online Databases and Web Servers for Drug Metabolism Research</b>	<b>53</b>
	<i>David S. Wishart</i>	
3.1	Introduction	53
3.2	Online Drug Metabolism Databases	54
3.2.1	DrugBank	57
3.2.2	HMDB	59
3.2.3	PharmGKB	59
3.2.4	Wikipedia	60
3.2.5	PubChem	61
3.2.6	Synoptic Databases: ChEBI, ChEMBL, KEGG, and BindingDB	61
3.2.7	Specialized Databases: UM-BBD, SuperCYP, PKKB, and PK/DB	63
3.2.8	Online Database Summary	64
3.3	Online Drug Metabolism Prediction Servers	65
3.3.1	Metabolite Predictors	66
3.3.2	SoM Predictors	66
3.3.3	Specialized Predictors	68
3.3.4	ADMET Predictors	70
3.3.5	Web Server Summary	71
	References	71

### Part Three Computational Approaches to Study Cytochrome P450 Enzymes 75

<b>4</b>	<b>Structure and Dynamics of Human Drug-Metabolizing Cytochrome P450 Enzymes</b>	<b>77</b>
	<i>Ghulam Mustafa, Xiaofeng Yu, and Rebecca C. Wade</i>	
4.1	Introduction	77
4.2	Three-Dimensional Structures of Human CYPs	78
4.3	Structural Features of CYPs	78

4.3.1	CYP-Electron Transfer Protein Interactions	81
4.3.2	Substrate Recognition Sites	82
4.3.3	Structural Variability and Substrate Specificity Profiles	83
4.3.3.1	CYP1A2	83
4.3.3.2	CYP2A6	85
4.3.3.3	CYP2C9	85
4.3.3.4	CYP2D6	86
4.3.3.5	CYP2E1	87
4.3.3.6	CYP3A4	87
4.4	Dynamics of CYPs	88
4.4.1	Active Site Flexibility	88
4.4.2	Active Site Solvation	93
4.4.3	Active Site Access and Egress Pathways	93
4.4.4	MD Simulations of CYPs in Lipid Bilayers	96
4.5	Conclusions	96
	References	97
<b>5</b>	<b>Cytochrome P450 Substrate Recognition and Binding</b>	<b>103</b>
	<i>Andrew G. Leach and Nathan J. Kidley</i>	
5.1	Introduction	103
5.2	Substrate Recognition in the Catalytic Cycle of CYPs	103
5.3	Substrate Identity in Various Species	104
5.4	Structural Insight into Substrate Recognition by CYPs	107
5.4.1	CYP1A1, CYP1A2, and CYP1B1	108
5.4.2	CYP2A6	108
5.4.3	CYP2A13	109
5.4.4	CYP2C8	110
5.4.5	CYP2C9	112
5.4.6	CYP2D6	112
5.4.7	CYP2E1	113
5.4.8	CYP2R1	113
5.4.9	CYP3A4	115
5.4.10	CYP8A1	115
5.4.11	CYP11A1	116
5.4.12	CYP11B2	118
5.4.13	CYP19A1	118
5.4.14	CYP46A1	119
5.4.15	General Insights from Protein–Ligand Crystal Structures	119
5.5	The Challenges of Using Docking for Predicting Kinetic Parameters	120
5.6	Substrate Properties for Various Human Isoforms	120
5.6.1	Kinetic Parameters $K_m$ and $k_{cat}$ and Their Relationship with Substrate and Protein Structure	124
5.7	Conclusions	128
	References	128

<b>6</b>	<b>QM/MM Studies of Structure and Reactivity of Cytochrome P450 Enzymes: Methodology and Selected Applications</b>	<b>133</b>
	<i>Sason Shaik, Hui Chen, Dandamudi Usharani, and Walter Thiel</i>	
6.1	Introduction	133
6.2	QM/MM Methods	135
6.2.1	Methodological Issues in QM/MM Studies	136
6.2.1.1	QM/MM Partitioning	136
6.2.1.2	QM Methods	137
6.2.1.3	MM Methods	138
6.2.1.4	Subtractive versus Additive QM/MM Schemes	139
6.2.1.5	Electrostatic QM/MM Interactions	139
6.2.1.6	QM/MM Boundary Treatments	139
6.2.1.7	QM/MM Geometry Optimization	140
6.2.1.8	QM/MM Molecular Dynamics and Free Energy Calculations	140
6.2.1.9	QM/MM Energy versus Free Energy Calculations	141
6.2.2	Practical Issues in QM/MM Studies	141
6.2.2.1	QM/MM Software	141
6.2.2.2	QM/MM Setup	142
6.2.2.3	Accuracy of QM/MM Results	143
6.2.2.4	QM/MM Geometry Optimization	143
6.2.2.5	Extracting Insights from QM/MM Calculations	144
6.3	Selected QM/MM Applications to Cytochrome P450 Enzymes	144
6.3.1	Formation of Cpd I from Cpd 0	146
6.3.1.1	Conversion of Cpd 0 into Cpd I in the T252X Mutants	148
6.3.2	Properties of Cpd I	151
6.3.2.1	Cpd I Species of Different Cytochrome P450s	154
6.3.3	The Mechanism of Cytochrome P450 StaP	155
6.3.4	The Mechanism of Dopamine Formation	160
6.3.4.1	The Electrostatic Effect is Not Due to Simple Bulk Polarity	163
6.4	An Overview of Cytochrome P450 Function Requires Reliable MD Calculations	163
6.5	Conclusions	164
	References	165
<b>7</b>	<b>Computational Free Energy Methods for Ascertaining Ligand Interaction with Metabolizing Enzymes</b>	<b>179</b>
	<i>Mark J. Williamson</i>	
7.1	Introduction	179
7.2	Linking Experiment and Simulation: Statistical Mechanics	180
7.2.1	A Note on Chemical Transformations	182
7.3	Taxonomy of Free Energy Methods	183
7.3.1	Pathway Methods	183
7.3.1.1	Pathway Planning: Using the State Nature of the Free Energy Cycle	184
7.3.1.2	Free Energy Perturbation	185

7.3.1.3	Bennett Acceptance Ratio	185
7.3.1.4	Thermodynamic Integration	186
7.3.2	Endpoint Methods	186
7.3.2.1	Molecular Mechanics-Generalized Born Surface Area (MM-GBSA)	186
7.3.2.2	Linear Interaction Energy	187
7.3.2.3	QM Endpoint Methods	187
7.3.3	Summary of Free Energy Methods	187
7.4	Ligand Parameterization	188
7.5	Specific Examples	189
7.5.1	Cytochrome P450 (CYP)	189
7.5.2	Chorismate Mutase	192
7.6	Conclusions	192
	References	193
<b>8</b>	<b>Experimental Approaches to Analysis of Reactions of Cytochrome P450 Enzymes</b>	<b>199</b>
	<i>Frederick Peter Guengerich</i>	
8.1	Introduction	199
8.2	Structural Data and Substrate Binding	199
8.3	Systems for Production of Reaction Products and Analysis of Systems	200
8.3.1	<i>In Vivo</i> Systems	201
8.3.2	Tissue Microsomal Systems	201
8.3.3	Purified CYPs in Reconstituted Systems	201
8.3.4	Membranes from Heterologous Expression Systems	202
8.3.4.1	Mammalian Cells	202
8.3.4.2	Insect Cell Systems (Using Baculovirus Infection for Expression)	202
8.3.4.3	Microbial Membrane Systems	202
8.4	Methods for Analysis of Products of Drugs	203
8.4.1	Separation Methods	203
8.4.1.1	High-Performance Liquid Chromatography	203
8.4.1.2	Other Separation Methods	204
8.4.2	Analysis Methods	204
8.4.2.1	HPLC–UV	204
8.4.2.2	LC–MS	205
8.4.2.3	LC–MS/MS	205
8.4.2.4	LC–HRMS	205
8.4.2.5	NMR	205
8.4.2.6	Other Spectroscopy of Metabolites	206
8.5	Untargeted Searches for CYP Reactions	208
8.6	Complex CYP Products	208
8.7	Structure–Activity Relationships Based on Products	210
8.7.1	SARs Based on Chemical Bond Energy	211
8.7.2	SARs Based on Docking	211

8.7.3	Knowledge-Based SAR	212
8.8	SAR of Reaction Rates	213
8.9	Other Issues in Predictions	213
8.10	Conclusions	214
	References	214

## **Part Four Computational Approaches to Study Sites and Products of Metabolism 221**

<b>9</b>	<b>Molecular Interaction Fields for Predicting the Sites and Products of Metabolism</b>	<b>223</b>
	<i>Fabio Broccatelli and Nathan Brown</i>	
9.1	Introduction	223
9.2	CYP from a GRID Perspective	224
9.3	From Lead Optimization to Preclinical Phases: the Challenge of SoM Prediction	226
9.3.1	MetaSite: Accessibility Function	227
9.3.2	MetaSite: Reactivity Function	229
9.3.3	MetaSite: Site of Metabolism Prediction	230
9.3.4	MetaSite: Validation and Case Studies	231
9.3.5	MetaSite: Prediction of CYP Inhibition	234
9.3.6	MassMetaSite: Automated Metabolite Identification	236
9.4	Conclusions	239
	References	241
<b>10</b>	<b>Structure-Based Methods for Predicting the Sites and Products of Metabolism</b>	<b>243</b>
	<i>Chris Oostenbrink</i>	
10.1	Introduction	243
10.2	6 Å Rule	243
10.3	Methodological Approaches	245
10.4	Prediction of Binding Poses	247
10.5	Protein Flexibility	249
10.6	Role of Water Molecules	254
10.7	Effect of Mutations	256
10.8	Conclusions	258
	References	259
<b>11</b>	<b>Reactivity-Based Approaches and Machine Learning Methods for Predicting the Sites of Cytochrome P450-Mediated Metabolism</b>	<b>265</b>
	<i>Patrik Rydberg</i>	
11.1	Introduction	265
11.2	Reactivity Models for CYP Reactions	268

11.2.1	Hydroxylation of Aliphatic Carbon Atoms	268
11.2.2	Hydroxylation and Epoxidation of Aromatic and Double Bonded Carbon Atoms	271
11.2.3	Combined Carbon Atom Models	273
11.2.4	Comprehensive Models	273
11.3	Reactivity-Based Methods Applied to CYP-Mediated Site of Metabolism Prediction	274
11.3.1	Methods Only Applicable to Carbon Atoms	274
11.3.2	Comprehensive Methods	276
11.4	Machine Learning Methods Applied to CYP-Mediated Site of Metabolism Prediction	278
11.4.1	Atomic Descriptors	278
11.4.2	Machine Learning Methods and Optimization Criteria	279
11.5	Applications to SoM Prediction	280
11.5.1	Isoform-Specific Models	281
11.5.2	Isoform-Unspecific Models	283
11.6	Combinations of Structure-Based Models and Reactivity	284
11.7	Conclusions	285
	References	286

## **12 Knowledge-Based Approaches for Predicting the Sites and Products of Metabolism 293**

*Philip Neville Judson*

12.1	Introduction	293
12.2	Building and Maintaining a Knowledge Base	295
12.3	Encoding Rules in a Knowledge Base	299
12.4	Ways of Working with Rules	301
12.5	Using the Logic of Argumentation	303
12.6	Combining Absolute and Relative Reasoning	307
12.7	Combining Predictions from Multiple Sources	310
12.8	Validation and Assessment of Performance	312
12.9	Conclusions	314
	References	314

## **Part Five Computational Approaches to Study Enzyme Inhibition and Induction 319**

### **13 Quantitative Structure–Activity Relationship (QSAR) Methods for the Prediction of Substrates, Inhibitors, and Inducers of Metabolic Enzymes 321**

*Oraphan Phuangsawai, Supa Hannongbua, and Mathew Paul Gleeson*

13.1	Introduction	321
13.2	<i>In Silico</i> QSAR Methods	322
13.2.1	Experimental Variability	323

13.2.2	Data Curation and Manipulation	324
13.2.3	Molecular Descriptors	324
13.2.4	Training SAR, QSAR, and Machine Learning Models	325
13.2.5	Local versus Global QSAR Models	325
13.2.6	SAR and Classical QSAR Methods	326
13.2.7	Machine Learning QSAR Methods	327
13.2.8	Model Assessment and Validation	327
13.2.8.1	Assessing the Predictive Ability of QSAR Models	327
13.2.8.2	Applicability Domains of QSAR Models	328
13.3	QSAR Models for Cytochrome P450	328
13.3.1	Inhibition QSAR	328
13.3.1.1	SAR	328
13.3.1.2	Classical QSAR Models	329
13.3.1.3	Machine Learning QSAR Models	333
13.3.1.4	Classification Models	334
13.3.1.5	3D QSAR Models	335
13.3.2	Enzyme Induction QSAR	336
13.4	Conjugative Metabolizing Enzymes	337
13.4.1	Uridine Diphosphate Glucosyltransferase (UGT) QSAR	338
13.4.2	Sulfotransferases QSAR	338
13.5	<i>In Vitro</i> Clearance QSAR	339
13.6	Conclusions	340
	References	341
<b>14</b>	<b>Pharmacophore-Based Methods for Predicting the Inhibition and Induction of Metabolic Enzymes</b>	<b>351</b>
	<i>Teresa Kaserer, Veronika Temml, and Daniela Schuster</i>	
14.1	Introduction	351
14.2	Substrate and Inhibitor Pharmacophore Models	354
14.2.1	Cytochrome P450 enzymes	354
14.2.1.1	CYP1A2	354
14.2.1.2	CYP2B6	355
14.2.1.3	CYP2C9	356
14.2.1.4	CYP2C19	357
14.2.1.5	CYP2D6	358
14.2.1.6	CYP3A4	359
14.2.1.7	CYP3A5 and CYP3A7	360
14.2.2	UDP-Glucuronosyltransferases (UGTs)	361
14.2.2.1	UGT1A1	361
14.2.2.2	UGT1A4	361
14.2.2.3	UGT1A9	361
14.2.2.4	UGT2B7	362
14.2.3	Interference with Recently Identified Phase I Metabolic Enzymes	362
14.3	Inducer Models	363
14.3.1	Hetero- and Autoactivation	363



14.3.1.1	CYP2C9	363
14.3.1.2	CYP3A4	364
14.3.2	Nuclear Receptors	364
14.3.2.1	Pregnane X Receptor	364
14.3.2.2	CAR	366
14.4	Conclusions	366
	References	368
15	<b>Prediction of Phosphoglycoprotein (P-gp)-Mediated Disposition in Early Drug Discovery</b>	<b>373</b>
	<i>Simon Thomas and Richard J. Dimelow</i>	
15.1	Introduction	373
15.2	QSAR Modeling of Compounds Interacting with Transporters	376
15.2.1	Experimental Data and Assays	376
15.2.2	Descriptors Used in P-gp Substrate Identification	378
15.2.3	QSAR Methods Used in P-gp Substrate Identification	380
15.3	Influence of Compound Structure on P-gp Substrate Identity	380
15.4	QSAR Models for P-gp Substrates	385
15.5	Application to Drug Discovery	388
15.6	Conclusions	391
	References	392
16	<b>Predicting Toxic Effects of Metabolites</b>	<b>397</b>
	<i>Andreas Bender</i>	
16.1	Introduction	397
16.2	Methods for Predicting Toxic Effects	401
16.2.1	Predicting Metabolites	401
16.2.2	Predicting Relative and Absolute Metabolism Likelihoods and Rates	401
16.2.3	Utilizing Pharmacogenetic Data to Anticipate Dose, Rate, and Time Information in an Individual Patient	402
16.2.4	Predicting the Effect of the Resulting Metabolites	402
16.2.4.1	Bioactivity-Based Mechanistic Models	403
16.2.4.2	Incorporating Pathway Information into Toxicity Models	404
16.2.4.3	Toxicogenetic and Pharmacogenomic Approaches	406
16.2.4.4	Knowledge-Based Systems	407
16.2.4.5	Reactive Metabolites	407
16.2.5	Current Scientific and Political Developments Regarding Metabolism and Toxicity Prediction	408
16.3	Conclusions	408
	References	409

**Part Six Experimental Approaches to Study Metabolism 413**

- 17 *In Vitro* Models for Metabolism: Applicability for Research on Food Bioactives 415**  
*Natalie D. Glube and Guus Duchateau*
  - 17.1 Introduction 415
    - 17.1.1 Bioavailability 416
    - 17.1.2 Intestinal Absorption 416
    - 17.1.3 First-Pass Metabolism 418
  - 17.2 Classification of *In Vitro* Models for Metabolism 418
  - 17.3 Modifications via Gut (Colon) Microflora 419
    - 17.3.1 Background Information 419
    - 17.3.2 *In Vitro* Models 420
      - 17.3.2.1 Fecal Slurry 421
      - 17.3.2.2 Isolated Pure Bacterial Cultures 421
      - 17.3.2.3 Complex Intestinal Models (TIM-2) 421
  - 17.4 Intestinal (Gut Wall) Metabolism 421
    - 17.4.1 Background Information 421
    - 17.4.2 *In Vitro* Models 422
      - 17.4.2.1 Tissue Intact Models 423
      - 17.4.2.2 Subcellular and Cellular Models 423
  - 17.5 Hepatic Metabolism 423
    - 17.5.1 Background Information 423
    - 17.5.2 *In Vitro* Models 424
      - 17.5.2.1 Supersomes: Recombinant Phase I and Phase II Enzymes 424
      - 17.5.2.2 Microsomes 424
      - 17.5.2.3 S9 Fractions 426
      - 17.5.2.4 Hepatocyte Cell Lines 426
      - 17.5.2.5 Primary Cultures: Cryopreserved Hepatocytes 427
      - 17.5.2.6 Cryopreserved Hepatocytes versus Microsomes 428
      - 17.5.2.7 Hepatocytes in Culture 429
  - 17.6 Pharmacokinetic Data Obtainable from *In Vitro* Metabolism Models 431
    - 17.6.1 Pharmacokinetic Analysis 431
      - 17.6.1.1 Measurement Methodology: Substrate Depletion versus Metabolite Formation 432
      - 17.6.1.2 Mathematical Models for Metabolism: Well-Stirred, Parallel Tube, and Dispersion Models 432
    - 17.7 Assay Validation 433
      - 17.7.1 Selection and Preparation of Reference Compounds 433
      - 17.7.2 Analytics 434
      - 17.7.3 Theoretical Steps to Establish an *In Vitro* Model 434
    - 17.8 Conclusions 435
      - 17.8.1 What Can We Summarize from the Literature? 435

17.8.2	What Questions We Wish to Have Answered Will Determine Which Model We Select	436
	References	438
<b>18</b>	<b><i>In Vitro</i> Approaches to Study Drug–Drug Interactions</b>	<b>441</b>
	<i>Stephen S. Ferguson and Jessica A. Bonzo</i>	
18.1	Introduction	441
18.1.1	Additional Factors Influencing Drug Metabolism	442
18.2	Inhibition of Drug Metabolism	444
18.2.1	<i>In Vitro</i> Models for Predicting Inhibition of Drug Metabolism	444
18.2.1.1	Human Liver Microsomes	445
18.2.1.2	S9 and Cytosol	456
18.2.1.3	Recombinant Enzymes	457
18.2.1.4	Primary Hepatocytes	458
18.3	Transcriptional Regulation of Metabolism	460
18.3.1	Gene Induction Pathways	460
18.3.2	Gene Repression/Suppression	462
18.3.3	<i>In Vitro</i> Models for Predicting Induction of Drug Metabolism Enzymes	463
18.3.3.1	Ligand Binding Assays	463
18.3.3.2	Gene Reporter Assays	465
18.3.3.3	Cellular Models for Induction Studies	466
18.3.3.4	Induction Assays in Cellular Models	468
18.3.3.5	Treatment with Control and Test Compounds	470
18.3.3.6	Gene Expression in Cellular Models for Induction	471
18.3.3.7	Enzymatic Activity in Metabolically Competent Cellular Models of Induction	474
18.4	Next-Generation Models and Concluding Remarks	474
	References	477
<b>19</b>	<b>Metabolite Detection and Profiling</b>	<b>485</b>
	<i>Ian D. Wilson</i>	
19.1	Introduction	485
19.2	Chromatography	486
19.3	Mass Spectrometry	487
19.4	Sample Preparation for LC–MS–Based Metabolite Profiling	490
19.5	Metabolic Profiling by LC–MS	491
19.5.1	Metabolic Stability and Cytochrome P450 Inhibition Assays	491
19.5.2	Metabolite Profiling, Detection, and Identification from <i>In Vivo</i> and <i>In Vitro</i> Studies	492
19.5.3	Reactive Metabolite Detection	496
19.6	Conclusions	496
	References	497
	<b>Index</b>	<b>499</b>